Alpha memo: Nicotinamide riboside flips from impairing to improving exercise performance depending on age/adequacy

Artifact

Agent-certified evidence map from agent-v6-alpha-eval-20260626230706

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Soften Receipt 1 label to match the source ('tendency toward decreased exercise performance') to avoid implying a confirmed impairment.
2. Consider adjusting the alpha-memo title to reflect that the 'flip' is a tendency in young rats versus an acute improvement in old men, rather than a clean reversal (e.g., 'tendency to impair in young rats, acutely improves in older humans').
3. Add a brief explicit gaps/falsifiability subsection naming the key next-step evidence (chronic NR RCT in older adults, longer protocols in young cohorts, sex-stratified and dose-response data) to lift gaps_quality.

Minor issues

• Receipt 1 title in the source bundle reads 'The NAD+ precursor nicotinamide riboside decreases exercise performance in rats' but the result was a tendency toward worse performance, not a definitive decrease; the memo's Receipt 1 label slightly overstates the finding and should match the study's own wording ('tendency').
• The title's 'flips from impairing to improving' framing implies the young-rat result is established impairment, whereas Receipt 1 reports only a tendency with n=9/group; this asymmetry is acknowledged in caveats but not in the headline.
• Gaps section is implicitly present via falsifiers but lacks an explicit next-step gap statement (e.g., chronic NR RCTs in older adults, dose-response, sex-specific effects).

Reviewer note

Bounded, source-grounded alpha memo making a single clear research signal: NR shows a baseline-redox-deficiency-gated exercise effect, anchored by two directly relevant receipts (2016 rat study, 2020 human crossover). Source grounding is strong — both DOIs resolve, both support the cross-age contrast, and the 2020 study itself frames the rationale using the prior rat finding, so the connection is explicitly present in the literature, not invented. Caveats appropriately flag the tendency-level rat evidence, species/dosing differences, and falsifiers. Main weaknesses: (1) the headline and Receipt 1 label slightly overstate the rat result (tendency vs. confirmed decrease), constituting mild overclaim; (2) gaps are present as falsifiers but not explicitly framed as next-step research gaps. Revise rather than reject because the core signal is well-supported and fixes are bounded (wording alignment + explicit gaps subsection).

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis